phase 2_completion
saveGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer